Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis

doi:10.4254/wjh.v9.i30.1166

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 30

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9534)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

578

WORD

210

HTML

5049

Figures (1-2)

181

Tables (1-1)

186

Sum=6204

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

493

Download

722

Sum=1215

Publishing Process of This Article

Item

Count

Browse

1008

Download

1107

Sum=2115

Oct 28, 2017 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (36)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Oct 28, 2017; 9(30): 1166-1175
Published online Oct 28, 2017. doi: 10.4254/wjh.v9.i30.1166

Open in New Tab Full Size Figure Download Figure

Figure 1 Worldwide prevalence of spontaneous bacterial peritonitis due to Gram-positive bacteria.

Open in New Tab Full Size Figure Download Figure

Figure 2 Infection management algorithm of spontaneous peritonitis due to Gram-positive bacteria[45,46,51,54,61,62,65,72,80,82-84]. AMP: Ampicillin; CFX: Cefotaxime; CFZ: Cefazolin; CPT: Ceftaroline; CTX: Ceftriaxone; DAP: Daptomycin; EAT: Empiric antibacterial therapy; GEN: Gentamicin; LNZ: Linezolid; MDR: Multidrug resistant; MER: Meropenem; MRSA: Methicillin-resistant S. aureus; MSSA: Methicillin-susceptible S. aureus; OXA: Oxacillin; PMN: Polymorphonuclear; TGC: Tigecycline; VAN: Vancomycin; VRE: Vancomycin-resistant enterococci.

Citation: Fiore M, Maraolo AE, Gentile I, Borgia G, Leone S, Sansone P, Passavanti MB, Aurilio C, Pace MC. Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis. World J Hepatol 2017; 9(30): 1166-1175
URL: https://www.wjgnet.com/1948-5182/full/v9/i30/1166.htm
DOI: https://dx.doi.org/10.4254/wjh.v9.i30.1166